We found that salvage therapy with CD19/CD22 CAR T cell infusions or CD19/CD22 CAR T cell infusions combined with ASCT is effective in some adult patients with r/r Burkitt lymphoma. The gene discussed is CD22; the disease is Burkitt lymphoma.